This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wise, R.
Right arrow Articles by Andrews, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wise, R.
Right arrow Articles by Andrews, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 428-430, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Pharmacokinetics and Inflammatory Fluid Penetration of Clinafloxacin

R. Wise,* S. Jones, I. Das, and J. M. Andrews

Department of Microbiology, City Hospital NHS Trust, Birmingham, United Kingdom

Received 24 March 1997/Returned for modification 18 September 1997/Accepted 15 November 1997

A single 200-mg dose of clinafloxacin was given orally to each of nine healthy male volunteers, and the concentrations of the drug were measured in plasma, cantharidin-induced inflammatory fluid, and urine over the following 24 h (48 h in the case of urine). The mean maximum concentration in plasma was 1.34 µg/ml at a mean time of 1.8 h postdose. The mean maximum concentration in the inflammatory fluid was 1.3 µg/ml at 3.8 h postdose. The mean elimination half-life of clinafloxacin in plasma was 5.65 h. The overall penetration into the inflammatory fluid was 93.1%, as assessed by determining the ratio of area under the concentration-time curves. Recovery of clinafloxacin in urine was 58.8% by 24 h and 71.8% by 48 h postdose.


* Corresponding author. Mailing address: Department of Microbiology, City Hospital NHS Trust, Dudley Rd., Birmingham B18 7QH, United Kingdom. Phone: 121-554-3801, ext. 4255. Fax: 121-551-7763. E-mail: r.wise{at}bham.ac.uk.


Antimicrobial Agents and Chemotherapy, February 1998, p. 428-430, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]  
  • Randinitis, E. J., Brodfuehrer, J. I., Eiseman, I., Vassos, A. B. (2001). Pharmacokinetics of Clinafloxacin after Single and Multiple Doses. Antimicrob. Agents Chemother. 45: 2529-2535 [Abstract] [Full Text]  
  • Siami, G., Christou, N., Eiseman, I., Tack, K. J., the Clinafloxacin Severe Skin And Soft Tissue Infe, (2001). Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections. Antimicrob. Agents Chemother. 45: 525-531 [Abstract] [Full Text]  
  • Snydman, D. R., Jacobus, N. V., McDermott, L. A., Supran, S. E. (2000). Comparative In Vitro Activities of Clinafloxacin and Trovafloxacin against 1,000 Isolates of Bacteroides fragilis Group: Effect of the Medium on Test Results. Antimicrob. Agents Chemother. 44: 1710-1712 [Abstract] [Full Text]  
  • Trampuz, A., Wenk, M., Rajacic, Z., Zimmerli, W. (2000). Pharmacokinetics and Pharmacodynamics of Levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in Human Skin Blister Fluid. Antimicrob. Agents Chemother. 44: 1352-1355 [Abstract] [Full Text]  
  • Fuchs, P. C., Barry, A. L., Brown, S. D. (1998). In Vitro Activities of Clinafloxacin against Contemporary Clinical Bacterial Isolates from 10 North American Centers. Antimicrob. Agents Chemother. 42: 1274-1277 [Abstract] [Full Text]